Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.52 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403116 | 0.87 | GRM8 (0.61) | LMNAGRM8GRM6GRM7GRM4 | |
| SCHEMBL9061995 | 0.85 | GRM8 (0.59) | LMNAGRM8GRM6GRM7GRM4 | |
| SCHEMBL12145017 | 0.85 | AKR1B1 (0.54) | TSHRSLC22A6GPR84FFAR1FFAR4 | |
| SCHEMBL338706 | 0.85 | AKR1B1 (0.54) | TSHRSLC22A6GPR84FFAR1FFAR4 | |
| SCHEMBL339788 | 0.83 | GPR84 (0.56) | TSHRSLC22A6GPR84FFAR1FFAR4 | |
| SCHEMBL9291138 | 0.83 | GPR84 (0.56) | TSHRSLC22A6GPR84FFAR1FFAR4 | |
| SCHEMBL9290884 | 0.83 | GPR84 (0.56) | TSHRSLC22A6GPR84FFAR1FFAR4 | |
| SCHEMBL9290873 | 0.83 | GPR84 (0.56) | TSHRSLC22A6GPR84FFAR1FFAR4 | |
| SCHEMBL339162 | 0.82 | GABBR2 (0.57) | GRM8GRM6GRM7GRM4TSHR | |
| SCHEMBL18096828 | 0.80 | GPR84 (0.52) | LMNANFKB1TSHRPMP22SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-10010618-B2 | Methods for treating cancer using combination therapies | ENDOCYTE, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170258923-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2017-09-14 | — | — | US | disclosed |
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | ENDOCYTE INC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | ENDOCYTE, INC | 2016-10-06 | — | — | US | disclosed |
| US-9415113-B2 | Targeting monomers and polymers having targeting blocks | UNIVERSITY OF WASHINGTON (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160067341-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2016-03-10 | — | — | US | disclosed |
| US-9193763-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2015-11-24 | — | — | US | disclosed |
| US-8907058-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140154702-A1 | Methods For Treating Cancer Using Combination Therapies | ENDOCYTE INC (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140073763-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130011362-A1 | TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS | PHASERX, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2066/4885GRM8 469/4885GRM6 932/4885 |
| US-20130011362-A1 | TARGETING MONOMERS AND POLYMERS HAVING TARGETING BLOCKS | FOLR1, FOLR2, DHFR | LMNA 2061/4885GRM8 758/4885GRM6 559/4885 |
| US-10010618-B2 | Methods for treating cancer using combination therapies | SLC7A11, CXCR2, TPX2 | LMNA 4453/4885GRM8 1008/4885GRM6 1036/4885 |
| US-20110288152-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2258/4885GRM8 569/4885GRM6 991/4885 |
| US-20160296630-A1 | METHODS FOR TREATING CANCER USING COMBINATION THERAPIES | SLC7A11, CXCR2, TPX2 | LMNA 4453/4885GRM8 1008/4885GRM6 1036/4885 |
| US-20170258923-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2066/4885GRM8 469/4885GRM6 932/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2066/4885GRM8 469/4885GRM6 932/4885 |
| US-20140073763-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2066/4885GRM8 469/4885GRM6 932/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | LMNA 2066/4885GRM8 469/4885GRM6 932/4885 |
| US-20160067341-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2066/4885GRM8 469/4885GRM6 932/4885 |
| US-20160287731-A1 | Compounds for Positron Emission Tomography | FOLH1, FOLR2, FOLR1 | LMNA 1873/4885GRM8 1867/4885GRM6 1001/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | LMNA 2066/4885GRM8 469/4885GRM6 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.